These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19577326)

  • 1. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study.
    Monheit GD; Cohen JL;
    J Am Acad Dermatol; 2009 Sep; 61(3):421-5. PubMed ID: 19577326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment.
    Rubin MG; Dover J; Glogau RG; Goldberg DJ; Goldman MP; Schlessinger J
    J Drugs Dermatol; 2009 May; 8(5):439-44. PubMed ID: 19537366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines.
    Moy R; Maas C; Monheit G; Huber MB;
    Arch Facial Plast Surg; 2009; 11(2):77-83. PubMed ID: 19289677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview.
    Rzany B; Ascher B; Monheit G
    J Eur Acad Dermatol Venereol; 2010 Jan; 24 Suppl 1():1-14. PubMed ID: 19930409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of the long-term safety data of repeat administrations of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Cohen JL; Schlessinger J; Cox SE; Lin X;
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S43-9. PubMed ID: 19945004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Rubin M; Dover J; Maas C; Nestor M
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.
    Monheit G; Carruthers A; Brandt F; Rand R
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S51-9. PubMed ID: 17241415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines.
    Ascher B; Zakine B; Kestemont P; Baspeyras M; Bougara A; Santini J
    J Am Acad Dermatol; 2004 Aug; 51(2):223-33. PubMed ID: 15280841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.
    Yablon SA; Brashear A; Gordon MF; Elovic EP; Turkel CC; Daggett S; Liu J; Brin MF
    Clin Ther; 2007 Apr; 29(4):683-90. PubMed ID: 17617291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients.
    Rzany B; Dill-Müller D; Grablowitz D; Heckmann M; Caird D;
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S18-25. PubMed ID: 17241409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clostridium botulinum type A toxin for the treatment of upper face animation lines: an Iranian experience.
    Farahvash MR; Arad S
    J Cosmet Dermatol; 2007 Sep; 6(3):152-8. PubMed ID: 17760691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.
    Brin MF; Comella CL; Jankovic J; Lai F; Naumann M;
    Mov Disord; 2008 Jul; 23(10):1353-60. PubMed ID: 18546321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Baumann L; Brandt FS; Kane MA; Donofrio LM
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding the use of neurotoxins in facial aesthetics: a consensus panel's assessment and recommendations.
    Kane M; Donofrio L; Ascher B; Hexsel D; Monheit G; Rzany B; Weiss R
    J Drugs Dermatol; 2010 Jan; 9(1 Suppl):s7-22; quiz s23-5. PubMed ID: 20919448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
    Coté TR; Mohan AK; Polder JA; Walton MK; Braun MM
    J Am Acad Dermatol; 2005 Sep; 53(3):407-15. PubMed ID: 16112345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study.
    Fagien S; Cox SE; Finn JC; Werschler WP; Kowalski JW
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S2-9. PubMed ID: 17241410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.
    Factor SA; Molho ES; Evans S; Feustel PJ
    Mov Disord; 2005 Sep; 20(9):1152-60. PubMed ID: 15954134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial.
    Yuan RY; Sheu JJ; Yu JM; Chen WT; Tseng IJ; Chang HH; Hu CJ
    Neurology; 2009 Apr; 72(17):1473-8. PubMed ID: 19246421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.
    Pannek J; Göcking K; Bersch U
    BJU Int; 2009 Nov; 104(9):1246-50. PubMed ID: 19426192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A.
    Lawrence I; Moy R
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S66-71. PubMed ID: 19945007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.